Cannabinol (CBN) and glaucoma

We wrote a survey last August of the possible use of cannabinoids in pharmaceutical intervention in glaucoma, a progressive degradation of retinal ganglion cells. Cannabinoids in general seem able to slow this degeneration, and to lower damaging intraocular pressure. 

One of them, cannabinol (CBN), was investigated at the University of British Columbia this year (Somvanshi RK, et al., Biolchim Biophys Acta Mol Basis Dis. 2022 Mar 1;1868(3):166325. doi: 10.1016/j.bbadis.2021.166325). The study aimed to evaluate its role, in vitro and in vivo, in neuroprotection and modulation of pressure, and its effects on extracellular matrix proteins.

In a mouse model, CBN was able to protect 661W retinal ganglion precursor-like cells from pressure-induced toxicity. In human trabecular meshwork cells, CBN attenuated changes in fibronectin α-smooth muscle actin, and mitogen-activated protein kinases, with and without transforming growth factor-beta 2-induced stress. Post-intravitreal CBN delivery in vivo also improved pattern electroretinogram amplitudes and reduced intraocular pressure in a rat episcleral vein laser photocoagulation model of glaucoma. 

PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis but without residual cannabinoids like THC or any of the impurities or chemicals associated with plant-derived production processes. Our molecular assembly technique, that synthesizes CBD from aromatic terpenes instead of cannabis, assures you the food and pharmaceutical-grade quality that you need for quality-conscious customers. If you are interested in PureForm CBD™ or want to partner on any other of the 140+ known cannabinoids, please contact Damian Peters at 310-666-4869, or emailinfo@pureformglobal.com. 

The foregoing is a report on trends and developments in the cannabinoid industry. No product described herein is intended to diagnose, treat, cure or prevent any disease or syndrome.